7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dementia is associated with medial temporal atrophy even after accounting for neuropathologies

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brain atrophy is associated with degenerative neuropathologies and the clinical status of dementia. Whether dementia is associated with atrophy independent of neuropathologies is not known. In this study, we examined the pattern of atrophy associated with dementia while accounting for the most common dementia-related neuropathologies. We used data from National Alzheimer’s Coordinating Center ( n = 129) and Alzheimer’s Disease Neuroimaging Initiative ( n = 47) participants with suitable in vivo 3D-T 1w MRI and autopsy data. We determined dementia status at the visit closest to MRI. We examined the following dichotomized neuropathological variables: Alzheimer’s disease neuropathology, hippocampal sclerosis, Lewy bodies, cerebral amyloid angiopathy and atherosclerosis. Voxel-based morphometry identified areas associated with dementia after accounting for neuropathologies. Identified regions of interest were further analysed. We used multiple linear regression models adjusted for neuropathologies and demographic variables. We also examined models with dementia and Clinical Dementia Rating sum of the boxes as the outcome and explored the potential mediating effect of medial temporal lobe structure volumes on the relationship between pathology and cognition. We found strong associations for dementia with volumes of the hippocampus, amygdala and parahippocampus (semi-partial correlations ≥ 0.28, P < 0.0001 for all regions in National Alzheimer’s Coordinating Center; semi-partial correlations ≥ 0.35, P ≤ 0.01 for hippocampus and parahippocampus in Alzheimer’s Disease Neuroimaging Initiative). Dementia status accounted for more unique variance in atrophy in these structures (∼8%) compared with neuropathological variables; the only exception was hippocampal sclerosis which accounted for more variance in hippocampal atrophy (10%). We also found that the volumes of the medial temporal lobe structures contributed towards explaining the variance in Clinical Dementia Rating sum of the boxes (ranging from 5% to 9%) independent of neuropathologies and partially mediated the association between Alzheimer’s disease neuropathology and cognition. Even after accounting for the most common neuropathologies, dementia still had among the strongest associations with atrophy of medial temporal lobe structures. This suggests that atrophy of the medial temporal lobe is most related to the clinical status of dementia rather than Alzheimer's disease or other neuropathologies, with the potential exception of hippocampal sclerosis.

          Abstract

          Woodworth et al. report that MRI-measured atrophy of the medial temporal lobe is strongly associated with dementia even after accounting for brain pathologies from an autopsy. This suggests atrophy seen on MRI is reflective of neurodegeneration not entirely accounted for by common pathologies including Alzheimer’s disease.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

          Neurology, 34(7), 939-939
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

            We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

              Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
                Bookmark

                Author and article information

                Journal
                Brain Commun
                Brain Commun
                braincomms
                Brain Communications
                Oxford University Press
                2632-1297
                2022
                07 March 2022
                07 March 2022
                : 4
                : 2
                : fcac052
                Affiliations
                [1 ] Department of Neurology, University of California , Irvine, CA, USA
                [2 ] Institute for Memory Impairments and Neurological Disorders, University of California , Irvine, CA, USA
                [3 ] Department of Radiology, University of Southern California , Los Angeles, CA, USA
                [4 ] Department of Pathology and Laboratory Medicine, University of California , Irvine, CA, USA
                [5 ] Department of Epidemiology, University of California , Irvine, CA, USA
                [6 ] Department of Neurobiology and Behavior, University of California , Irvine, CA, USA
                Author notes
                Correspondence to: Seyed Ahmad Sajjadi, MD, PhD Office 364, Med Surge II, Academy Way Irvine, CA 92697, USA E-mail: ssajjadi@ 123456uci.edu

                *Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.

                Author information
                https://orcid.org/0000-0002-6256-857X
                https://orcid.org/0000-0002-8960-2213
                Article
                fcac052
                10.1093/braincomms/fcac052
                8952251
                35350552
                41d4c097-ce7c-4aee-b89d-5563acce98e4
                © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 31 August 2021
                : 30 December 2021
                : 03 March 2022
                Page count
                Pages: 14
                Funding
                Funded by: National Institutes of Health’s, doi 10.13039/100000002;
                Funded by: National Institute on Aging, doi 10.13039/100000049;
                Award ID: R01AG062706
                Categories
                Original Article
                AcademicSubjects/MED00310
                AcademicSubjects/SCI01870

                dementia,mri,medial temporal lobe,atrophy,neuropathology
                dementia, mri, medial temporal lobe, atrophy, neuropathology

                Comments

                Comment on this article